Isarna Therapeutics Overview

  • Founded
  • 1998
Founded
  • Status
  • Private
  • Employees
  • 7
Employees
  • Latest Deal Type
  • 2ndary - Private
  • Investors
  • 6

Isarna Therapeutics General Information

Description

Developer of TGF-β inhibitors designed to treat ophthalmic and fibrotic diseases and fight cancer. The company's inhibitors offer a pipeline of novel oligonucleotides and combination modalities to transcend clinical response, enabling healthcare professionals to improve patient outcomes.

Contact Information

Formerly Known As
Antisense Pharma
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Uhlandstrasse 2
  • 80336 Munich
  • Germany
+49 089 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Isarna Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Secondary Transaction - Private 00000 Completed Clinical Trials - Phase 1
6. Later Stage VC 28-May-2014 000.00 00000 00000 Completed Clinical Trials - Phase 1
5. Later Stage VC 06-Jul-2011 000.00 00000 Completed Clinical Trials - Phase 1
4. Later Stage VC 15-Mar-2010 000.00 000.00 Completed Clinical Trials - Phase 1
3. Later Stage VC 08-Nov-2007 000.00 000.00 Completed Clinical Trials - Phase 1
2. Later Stage VC 30-Nov-2005 $18M $37.8M Completed Clinical Trials - Phase 1
1. Later Stage VC 29-Apr-2004 $19.8M $19.8M Completed Clinical Trials - Phase 1
To view Isarna Therapeutics’s complete valuation and funding history, request access »

Isarna Therapeutics Executive Team (9)

Name Title Board Seat Contact Info
Chris Huiskamp Chief Financial Officer
Rene Ruckert Chief Operating Officer
Karl-Hermann Schlingensiepen Co-Founder
Marion Munk MD Chief Medical Officer
Claus Schalper Chief Executive Officer
You’re viewing 5 of 9 executive team members. Get the full list »

Isarna Therapeutics Board Members (1)

Name Representing Role Since
Matthias Kromayer Ph.D MIG AG Board Member 000 0000
To view Isarna Therapeutics’s complete board members history, request access »

Isarna Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Isarna Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AT Newtec Venture Capital Minority 000 0000 000000 0
Sobera Capital PE/Buyout Minority 000 0000 000000 0
KfW IPEX-Bank Investment Bank Minority 000 0000 000000 0
MIG AG Venture Capital Minority 000 0000 000000 0
Global Chance Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »